KLK2: promising drug target in prostate cancer – a pipeline review

STUTTGART, Germany I August 31, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-KLK2 immunotherapeutics in R&D: Pipeline of KLK2-Targeted Immunotherapies.

This competitive intelligence report about Pipeline of KLK2-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting KLK2. This report will be prepared on demand within one working day upon order placement. The report lists KLK2 -targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of KLK2-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

This competitive intelligence report about KLK2-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting KLK2. This report will be prepared on demand within one working day upon order placement. The report lists KLK2-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of KLK2-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

Kallikrein-related peptidase 2 (KLK2) is a trypsin-like serine protease predominantly expressed in the prostate, and like PSA, KLK2 is regulated by androgens via androgen receptor (AR) signaling. Its normal physiological function includes the activation of pro-PSA and involvement in seminal clot liquefaction through the cleavage of semenogelins. Functionally, KLK2 can also activate other proteases and cleave extracellular matrix proteins, facilitating tumor invasion and metastasis.

Elevated KLK2 expression has been observed in prostate cancer tissues, with increased levels associated with high-grade tumors, metastatic potential, and biochemical recurrence after treatment. KLK2 also has restricted expression in prostate tissues, offering a promising profile for targeted therapy.

Recently published daa has shown high level KLK2 expression from localized prostate cancer through heavily treated metastatic castration-resistant prostate cancer, with even higher levels, homogenous immunostaining compared to PSMA. Importantly, KLK2 was found to be expressed on the surface of prostate cancer cells, rendering it accessible for targeting.

Preclinical studies have successfully shown prostate cancer cell targeting using various therapeutic modalities, including a T-cell engaging bispecific antibody and KLK2-targeted CAR-T cells. Preliminary clinical study results demonstrated early efficacy in a metastatic castration-resistant prostate cancer population, with incredibly low rates of treatment related adverse events. Thus, KLK2 represents a promising drug target in prostate cancer.

The report “Pipeline of KLK2-Targeted Immunotherapies” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-klk2-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation.

SOURCE: La Merie Publishing